Your browser doesn't support javascript.
loading
Subcellular specificity of cannabinoid effects in striatonigral circuits.
Soria-Gomez, Edgar; Pagano Zottola, Antonio C; Mariani, Yamuna; Desprez, Tifany; Barresi, Massimo; Bonilla-Del Río, Itziar; Muguruza, Carolina; Le Bon-Jego, Morgane; Julio-Kalajzic, Francisca; Flynn, Robyn; Terral, Geoffrey; Fernández-Moncada, Ignacio; Robin, Laurie M; Oliveira da Cruz, José F; Corinti, Simone; Amer, Yasmine Ould; Goncalves, Julia; Varilh, Marjorie; Cannich, Astrid; Redon, Bastien; Zhao, Zhe; Lesté-Lasserre, Thierry; Vincent, Peggy; Tolentino-Cortes, Tarson; Busquets-García, Arnau; Puente, Nagore; Bains, Jaideep S; Hebert-Chatelain, Etienne; Barreda-Gómez, Gabriel; Chaouloff, Francis; Lohman, Alexander W; Callado, Luis F; Grandes, Pedro; Baufreton, Jerome; Marsicano, Giovanni; Bellocchio, Luigi.
Afiliação
  • Soria-Gomez E; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa,
  • Pagano Zottola AC; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Mariani Y; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Desprez T; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Barresi M; University of Bordeaux, Bordeaux, France; IMN-UMR CNRS 5293 Neurodegenerative Diseases Institute, Bordeaux, France.
  • Bonilla-Del Río I; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa, Spain.
  • Muguruza C; Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.
  • Le Bon-Jego M; University of Bordeaux, Bordeaux, France; IMN-UMR CNRS 5293 Neurodegenerative Diseases Institute, Bordeaux, France.
  • Julio-Kalajzic F; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Flynn R; Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • Terral G; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Fernández-Moncada I; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Robin LM; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Oliveira da Cruz JF; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Corinti S; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Amer YO; Canada Research Chair in Mitochondrial Signaling and Physiopathology, Department of Biology, University of Moncton, Moncton, NB, Canada.
  • Goncalves J; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Varilh M; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Cannich A; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Redon B; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Zhao Z; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Lesté-Lasserre T; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Vincent P; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Tolentino-Cortes T; Department of Research and Development, IMG Pharma Biotech S.L., Derio, Spain.
  • Busquets-García A; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Puente N; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa, Spain.
  • Bains JS; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
  • Hebert-Chatelain E; Canada Research Chair in Mitochondrial Signaling and Physiopathology, Department of Biology, University of Moncton, Moncton, NB, Canada.
  • Barreda-Gómez G; Department of Research and Development, IMG Pharma Biotech S.L., Derio, Spain.
  • Chaouloff F; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France.
  • Lohman AW; Department of Cell Biology and Anatomy, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada.
  • Callado LF; Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Grandes P; Department of Neurosciences, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain; Achucarro Basque Center for Neuroscience, Leioa, Spain; Division of Medical Sciences, University of Victoria, Victoria, BC, Canada.
  • Baufreton J; University of Bordeaux, Bordeaux, France; IMN-UMR CNRS 5293 Neurodegenerative Diseases Institute, Bordeaux, France.
  • Marsicano G; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France. Electronic address: giovanni.marsicano@inserm.fr.
  • Bellocchio L; INSERM, U1215 NeuroCentre Magendie, Endocannabinoids and Neuroadaptation, Bordeaux, France; University of Bordeaux, Bordeaux, France. Electronic address: luigi.bellocchio@inserm.fr.
Neuron ; 109(9): 1513-1526.e11, 2021 05 05.
Article em En | MEDLINE | ID: mdl-33770505
ABSTRACT
Recent advances in neuroscience have positioned brain circuits as key units in controlling behavior, implying that their positive or negative modulation necessarily leads to specific behavioral outcomes. However, emerging evidence suggests that the activation or inhibition of specific brain circuits can actually produce multimodal behavioral outcomes. This study shows that activation of a receptor at different subcellular locations in the same neuronal circuit can determine distinct behaviors. Pharmacological activation of type 1 cannabinoid (CB1) receptors in the striatonigral circuit elicits both antinociception and catalepsy in mice. The decrease in nociception depends on the activation of plasma membrane-residing CB1 receptors (pmCB1), leading to the inhibition of cytosolic PKA activity and substance P release. By contrast, mitochondrial-associated CB1 receptors (mtCB1) located at the same terminals mediate cannabinoid-induced catalepsy through the decrease in intra-mitochondrial PKA-dependent cellular respiration and synaptic transmission. Thus, subcellular-specific CB1 receptor signaling within striatonigral circuits determines multimodal control of behavior.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Transdução de Sinais / Transmissão Sináptica / Receptor CB1 de Canabinoide Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Transdução de Sinais / Transmissão Sináptica / Receptor CB1 de Canabinoide Idioma: En Ano de publicação: 2021 Tipo de documento: Article